We are live on
!
Find out more
Puma Biotechnology
PBYI
PBYI
89 hedge funds and large institutions have $115M invested in Puma Biotechnology in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 23 increasing their positions, 26 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
308% more call options, than puts
Call options by funds: $870K | Put options by funds: $213K
76% more capital invested
Capital invested by funds: $65.5M → $115M (+$49.8M)
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
7% more funds holding
Funds holding: 83 → 89 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.45% less ownership
Funds ownership: 60.7% → 60.25% (-0.45%)
12% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 26
Holders
89
Holders Change
+6
Holders Change %
+7.23%
% of All Funds
1.43%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
23
Reduced
26
Closed
15
Calls
$870K
Puts
$213K
Net Calls
+$657K
Net Calls Change
-$278K
Top Buyers
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$2.42M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.4M |
| 3 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$1.26M |
| 4 |
BlackRock
New York
|
-$1.13M |
| 5 |
Millennium Management
New York
|
-$399K |
